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Abstract
Background: Resistin (Retn) is a cytokine which has a controversial physiological role regarding its involvement
with obesity and type II diabetes mellitus. Recently, murine Retn was found to be a possibly potential regulator of
hematopoiesis in mice shown in the screening results of a set of gene chips which mapped the expression level of
murine genes during regeneration of impaired bone marrow (BM) by 5-fluorouracil.
Results: Recombinant mice Retn was expressed in Escherichia coli and purified using ion exchange chromatography.
Totally 11.4 mg rmRetn was obtained from 500 ml culture with endotoxin level less than 1.0 EU/ug. The purity of
recombinant murine Resistin reached to at least 97.6 % via SDS-PAGE analysis and HPLC. The protein possessed
chemotaxis effects in the mouse aortic endothelial cells in vitro in transwell analysis. In vitro, rmRetn could up regulate
the CFU number of mice BM and after rmRetn was administered, the cell number of murine bone marrow was
significantly increased in vivo after chemotherapy. Finally, rmRetn was found able to protect mice from the
chemotoxicity of 5-fluorouracil.
Conclusions: The discovery demonstrated a new function of murine Retn and suggested that it could potentially
accelerate bone marrow regeneration post chemotherapy.
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Background
Identified in 2001 [1] as a new adipocytokine, Resistin
(Retn) is either known to be found in inflammatory zone
3 (Fiz3) as an adipocyte-specific secretory factor (ADSF).
The protein was named Retn because in many murine
obesity models, the circular level of Retn increases, indu-
cing insulin resistance [2–6]. Retn, a cysteine-rich pro-
tein secreted by the adipose tissue of rodents or by the
immune and epithelial cells of mammals, has a high se-
quence identity among species [7, 8]. In rodents, mem-
bers of the same family are mouse Retn-like alpha
(Retnla), beta (Retnlb) and gamma (Retnlg) [1, 9, 10].
However, only two of these analogs of the family, RETN
and RETNLB [11] were recognized in human beings,
which showed significant sequence homogeneity from
its murine orthologs [12]. Recently Retn was found in
energy metabolism and inflammatory response, which
suggests that Retn may act as a bridge linking the in-
flammation and insulin resistance [13]. In vitro studies
suggest that Retn acts as a pro-inflammatory cytokine
which activates endothelial cell functions inducing pro-
liferation and migration of smooth muscle, and promot-
ing macrophage lipid deposition. This results in lipid
metabolism and other processes which facilitate the oc-
currence of atherosclerosis and its development.
Besides the functions mentioned above, our lab acci-
dentally found Retn to exert effects on bone marrow re-
generation from the toxicity of chemopeutical agents.
Therefore, a hypothesis was suggested that there is a
strong relationship between Retn expression and damage
* Correspondence: wanxp@sjtu.edu.cn
6Department of Obstetrics and Gynecology, Shanghai First Maternity and
Infant Hospital, Tong Ji University School of Medicine, No.536, Changle Road,
Shanghai 200080, China
Full list of author information is available at the end of the article
© 2015 Wang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wang et al. BMC Biotechnology  (2015) 15:105 
DOI 10.1186/s12896-015-0221-1
or regeneration of bone marrow. Consequently, this
meant Retn may play a critical role in bone marrow re-
generation after damage, and eventually protect the
impaired tissues. It was obvious that it would be mean-
ingful to verify the new function of Retn and that it
might lead directly to a potential candidate or target for
relieving the bone marrow suppression by chemothera-
peutic agents, which is one of the main clinical side ef-
fects of chemotherapy.
Given the potential value of the hypothesis, it is neces-
sary to determine whether mouse Retn can protect bone
marrow from the damage of chemotherapeutic agents in
mouse models. For this reason, an abundance of high
quality and suitable murine models with impaired bone
marrow was prepared in advance.
In the present work, a feasible and cost-effective pre-
paring method for rmRetn was developed and an appro-
priate murine model of impaired bone marrow was




Our animal research carried out was in accordance with
the recommendations in the Guideline for the Care and
Use of Laboratory Animals of China. The protocol was
approved by the Committee on the Ethics of Animal Ex-
periments of school of pharmacy in Shanghai Jiaotong
University. All efforts were made to minimize animal
suffering.
Expression profile of mRetn in gene chip
In order to find proteins that exert the most effect on
bone marrow regeneration from the toxicity of chemo-
peutical agents, a group of 430 2.0 Affymetrix mouse
genome probe sets containing 39000 transcripts or
14000 genes, were screened. The hybridized total RNA
of mouse bone marrow was extracted at different times
post chemotherapy by 5-fluoracil in Balb/c mice.
ELISA of mouse Resistin
Mouse peripheral blood (PB) samples were obtained by
retro-orbital puncture. Each blood sample was coagu-
lated in the refrigerator at 4 °C, centrifuged at 1000 xg
for 15 min. The serum was collected and stored at −70 °C.
Aliquots were used once only for the test and were not
subjected to repeated freeze−thaw cycles. Murine Resistin
enzyme-linked immunosorbent assay (ELISA) kits were
used to measure Resistin serum levels according to the
instructions of the manufacturer.
Construction of the rmRetn expression plasmid
The mRetn coding sequence was cloned from the
cDNA, reversely transcribed from total mRNA of Balb/c
mouse liver tissues. The fragment was then amplified by
PCR using sense primer 5’-CATGCCATGGGGTCCAG
CATGCCACTGT-3’ and antisense primer 5’-CCCAAG
CTTTCAGGAAGCGACCTGCA-3’. The Xho I and
EcoR I sites (underlined) were incorporated into primers
to facilitate directional cloning of the PCR product into
the polyclonal sites of the expression vector pET28a(+)
(Novagen, USA). PCR was performed in the following
conditions: 94 °C for 2 min; 94 °C for 30 s, 55 °C for
20 s, 72 °C for 20 s, 32 cycles; 72 °C for 10 min. The
column-purified PCR product and vector was digested
with Xho I and EcoR I (Fermentas, Canada), purified
with agarose-gel, and ligated together. E. coli strain
DH5a (Novagen, USA) was chemically transformed with
the recombinant vector and cultured at 37 °C on Luria-
Bertani (LB) agar plates with kanamycin (0.1 mg/ml) in
order for a selection. Plasmid pET28a-rmRetn was con-
structed and analyzed by restrictive enzyme digestion
and finally confirmed by DNA sequencing (Genscript,
China).
Expression of rmRetn
The recombinant strain E. coli BL21 (DE3) (Novagen,
USA) harboring the plasmid pET28a-rmRetn was cul-
tured in 37 °C LB liquid medium containing 0.1 mg/ml
kanamycin, shaking at 250 rpm for 12 h. The culture
was sub-cultured into fresh LB medium at a ratio of 1:10
to the final medium volume under the same condition.
When the optical density (OD) of culture reached 0.8
at 600 nm, isopropyl-β-D-thiogalactopyranoside (IPTG)
(Merck, Germany) was added into the medium making a
final concentration of 1 mM in order to induce rmRetn
expression. The incubation was continued for another 8 h
at 42 °C, and cells were harvested by centrifugation at 12
000 rpm for 15 min and washed with phosphate-buffered
saline (1× PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM KH2PO4; pH 7.4).
Isolation, denaturation and refolding of rmRetn inclusion
body
10 ml ultrasonication buffer (1 × PBS, 1 mM EDTA,
0.1 mM PMSF; pH 7.4) was added to resuspend 0.5 g
cell paste. The suspension solution was then sonicated,
(Scientz, Ningbo, China) with 5 s working and 5 s rest-
ing in ice water as one cycle for 10 min in total. Then
bacterial inclusion bodies were collected by centrifuga-
tion at 12 000 rpm for 15 min at 4 °C. Then they were
washed once with PBS and centrifuged, and inclusion
bodies were resuspended in denaturing buffer (6 M
guanidine chloride, 1 mM EDTA, 50 mM NaCl, 50 mM
Tris–HCl) at a ratio 10:1 (mg:ml) and shaken for about
2 h until the inclusion body was dissolved thoroughly.
After centrifugation, the protein in the supernatant was
refolded by a slow dilution of the denaturing buffer into
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the renaturing buffer (1 mM reduced glutathione, 0.1 mM
oxidized glutathione, 0.5 M guanidine chloride, 0.4 M su-
crose, 0.1 M Tris–HCl; pH 6.0) of 100 volumes of the de-
naturing buffer with gentle shaking at room temperature
for 1 h and then followed by another 1 h shaking after di-
lution. After centrifugation at 15 000 rpm for 30 min, the
supernatant containing the renatured protein was pre-
pared for the following purification.
Purification of rmRetn
The protein in the dilution buffer was loaded continu-
ously onto a 20 ml Q sepharose column and then a
20 ml SP Sepharose column, which were well prequili-
brated with 20 ml buffer A (20 mM Tris–HCl, 1 mM
EDTA, 25 mM NaCl; pH 6.0), at a speed of 1 ml/min.
After the cation exchange column was removed away,
the protein was washed with 40 ml buffer A, and then
eluted using a 0–1.0 M NaCl gradient in the same buffer
with a speed of 1 ml/min. Fractions were collected accord-
ing to their UV absorption peaks and protein concentra-
tions were quantified using the Bradford method [14].
SDS-PAGE assay and western blotting
SDS-PAGE was performed using a 15 % running gel on
the Power-Pac Basic (Bio-Rad, USA). Briefly speaking, the
protein samples were loaded on the gel and were electro-
phoresed at 120 V for 1.5 h. The bands of proteins on the
gel were visualized by staining with Coomassie brilliant
blue R-250. In Western blotting experiments, proteins
were transferred onto polyvinylidene fluoride (PVDF)
membranes at 200 mA for 60 min. The membranes were
first blocked in PBS containing 10 % (w/v) non-fat milk,
and then incubated with a polyclonal antibody of mouse
Retn (R&D, USA), diluted at 1:2000 in PBS containing
0.05 % Tween 20 (PBST) and 5 % (w/v) non-fat milk.
After a washing, the membrane was incubated in the pres-
ence of horseradish peroxidase (HRP) conjugated second-
ary antibody (Jackson immuno, USA) diluted at 1:2 000 in
PBST with 5 % (w/v) non-fat milk powder. All the incu-
bating procedures were performed at 37 °C for 1 h or 4 °C
for overnight with gentle shaking and the membranes
were washed for three times before each incubation. Fi-
nally, the membrane was thoroughly rinsed five times with
PBST for 5 min each, and then the rmResitin protein was
visualized through enhanced electrogenerated chemilu-
minescence (ECL) reaction on X-ray film using western
blotting substrate reagent (Thermo, USA).
HPLC analysis
RP-HPLC was performed to determine the purity of
rmResistin with an ODS C18 column (4.6 × 250 mm,
5 μm) on Shimadzu LC 2010A HT (Shimadzu, Japan).
Twenty five microliters of rmRetn at 1 mg/ml in PBS was
loaded. The protein was eluted with acetonitrile solution
at a speed of 1 ml/min using an isocratic program at a
constant 70 % acetonitrile. The purity of the protein was
calibrated by the area normalization method of OD 280
peaks. SEC-HPLC was performed to determine the purity
and polymers of rmResistin using TSK-GEL G2000SWXL
(Tosoh, Japan) on ACME 9000 (Younglin, Korea). 50 μl of
rmRetn at 0.5 mg/ml in PBS was loaded. The protein was
eluted with phosphate buffer (1.27 mM Na2HPO4, 1.5 mM
KH2PO4, 0.4 M NaCl; unadjusted pH) at a speed of
0.8 ml/min. Absorbance at 280 nm was used to monitor
the elution profile.
Endotoxin assay
The endotoxin level of rmRestistin solution was de-
termined semi-quantitatively using the Chromogenic
Tachypleus Amebocyte Lysate (TAL) end-point assay kit
according to the protocol given by reagent supplier
(Xiamen Houshiji, Ltd., Xiamen, China). The assay was
the pharmaceutical industry standard procedure for qual-
ity control of biologics.
Bioactivity assay
Bioactivity of rmRetn was determined using a modified
Boyden chamber assay [15], following the protocol pro-
vided by BD company. Balb/c mouse aortic endothelial
cells (MAECs) were isolated and cultured as reported
previously [16]. Prior to each experiment, cells were sub-
jected to serum starvation in routine medium with only
1 % fetal bovine serum (Gibco, USA). The experiments
were performed as following: cell suspension (250 μl,
106 cells/well) was transferred to the transwells (Pore
size 8 um, Costar, MA), and then, 750 ul starvation
medium (supplanted with 1 % fetus bovine serum) with
or without rmRetn. The wells were incubated at 37 °C
with 5 % CO2 atmosphere for 5 h. The migratory cells
were qualified by counting five random microscopic
fields (×40) after dying with crystal violet. The assays
were performed in triples and the results were expressed
as a ratio of the total number of migrated cells in all five
fields of each well compared to the control.
BM CFU assay in vitro
In vitro bioactivity of the protein was detected by measur-
ing its BM cell proliferation-stimulating activity. Briefly
speaking, BM cells were obtained from the BM of male
SPF BALB/c mice as previously described [17], and then
added to culture dishes with methyl cellulose medium
(containing fetal calf serum, glutamine, β-mercaptoethanol
and IMDM), mixed with cytokines (mSCF, 10 ng/μL; mIL-
6, 10 ng/μL; mIL-3, 10 ng/μL; mTPO, 10 ng/μL; hG-CSF,
20 ng/μL; hEPO, 10 000U/mL, R&D systems, USA) and
different concentrations of rmRetn. PBS was used instead
of rmRetn in the control group. After incubated for 7 days
at 37 °C with 5 % CO2, the dishes were observed under a
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microscope, and the colonies (clusters with more than 50
cells are defined as colonies) were counted. The assay was
performed in triples and the results were expressed as
total number of CFU on each plate.
Mouse hematocyte instimulating assay
In vivo bioactivity of rmRetn was determined as follows:
Male BLAB/c mice aging 6–8 weeks (n = 64) were pur-
chased from Shanghai Slac Laboratory Animal Co.
(Shanghai, China). Mice were maintained under stand-
ard conditions and received humane care in accordance
with protocols approved by Shanghai Jiao Tong Univer-
sity and the legal requirements in China. The mice were
allowed to adapt to their environment for 1 week before
experiments. The mice were randomly assigned to 4
groups, with 16 animals in each group. In the experi-
ment group, the rmRetn was diluted in sterile PBS to a
concentration of 1, 10 and 100 μg/mL respectively, be-
fore it was used. The mice in three experiment groups
received single intraperitoneal injections of 100 ul at
doses of 5, 50 and 500 μg/kg body weight of rmRetn, re-
spectively. The mice in the control group were intraperi-
toneally injected with the same volume of PBS. The
mice received the injection of rmRetn or PBS every 12 h
for 168 h. Two time points during or post rmRetn ad-
ministration (that is day 5 and 10) are selected for
counting BM cells of mice.
Mouse survival rate protection assay
Male BLAB/c mice aging 6–8 weeks (n = 45) were used
in this experiment extending for two weeks. Mice were
randomly assigned to 3 groups with 15 animals in each
group. Mice in the first group were treated with single
intraperitoneal injection of rmRetn (250 μg/kg weight)
from day 0 to 4, once per day, and 5-Fluorouracil
(300 mg/kg weight) were injected at day 5. Mice in the
second group were injected with 5-Fu (300 mg/kg
weight) only. For the third group, mice were injected in-
traperitoneal of 5-Fu (300 mg/kg weight) first at day 0
and rmRetn (250 μg/kg weight) was used from the second
day to sixth day. The mice survival conditions were re-
corded and analyzed to investigate the effect of rmRetn on
the survival rate of mice.
Statistical analysis
All data was expressed as the mean ± Standard Deviation
(SD). The P values at the same time point are calculated
by one-way analysis of variance followed by 2-tailed
Student’s t-test. The difference of P values with less than
0.05 was considered significant in all experiments and is
indicated by symbols and the difference of P values with
less than 0.01 was considered extremely significant. Sur-
vival analysis was performed using log-rank test and
expressed as Kaplan-Meier survival curves. All statistical
analysis was performed using Statistical Product and Ser-
vice Solutions (SPSS; version 18.0) software (IBM, USA).
Results
5-Fu treatment induces expression of Retn in BM cells
In order to identify candidate genetic molecules contrib-
uting to the BM damage and regeneration, BM suppres-
sion was induced by a single injection of 5-Fu to normal
mice. Total BM cells reached the minimum at day 7,
then returned to normal level at day 21 post 5-Fu treat-
ment (Fig. 1a).
mRNA expression in total BM cells was profiled using
microarray. Immediately after impair, 567 of the 14000
detected genes were found to be increasingly expressed
and then they decreased, whose products was considered
as the most likely target proteins which were highly
expressed to initiate and promote the recovering pro-
gress of bone marrow. As a member of the gene clusters,
mRNA of Retn increased more than 2 folds compared to
the control in 3 days post 5-Fu injection, and then it
continued to increase more than 16 fold compared to
the control until 7 days later when it started to gradually
decrease to its normal level (Fig. 1b). Such a great
change only happened in rare genes.
Increases in the level of plasma Retn were observed at
day 7 (P = 0.008) and 11 (p = 0,026), recovering to pre-
treatment levels at day 14 following 5-Fu (Fig. 1c). The ex-
pression profiles of Retn correlated inversely to the BM
cellularity after 5-Fu treatment, which suggests that Retn
may play an important regulatory role in BM homeostasis.
Expression of the mature form of rmRetn in E. coli
The full length of mouse Retn cDNA is 1139 base pairs
(bps) with a coding sequence (CDS) of 345 bps position-
ing from 85 to 429 bp, encoding the full length protein
(GeneBank accession no. NM_022984.4). The first 60 bps
of CDS encode a signal peptide containing 20 amino
acids, which needs to be removed for maturation, so the
mature form of mouse Retn contains 94 amino acids. Ac-
cordingly, the recombinant mRetn (rmRetn) expressed in
prokaryotic expression system will consist of 95 amino
acids, coded by 285 base pairs, with an additional Met at
N-terminus. The theoretical pI of both mRetn and rmRetn
is 8.06. The amplified fragment from the cDNA library
was verified on agarose gel (Fig. 2a). Subcloned into E. coli
expression vector pET28a, the fragment sequence was
confirmed again by DNA sequencing.
After transformation, E. coli strain BL21 (DE3) har-
boring plasmid pET28a-rmRetn,cultured in LB liquid
medium and induced by IPTG, produced a protein posi-
tioned at about 10 KDa site on SDS-PAGE. The molecular
weight was 10.3 kDa which was calibrated based on the
shift rate of the marker bands, exactly equal to the theor-
etical molecular weight of rmRetn (Fig. 2b). The western
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blotting further indicated that the protein was rmRetn
which was expected. After sonication and centrifugation
at high speeds, the protein was found to exist only in a
pellet, which suggested that rmRetn was expressed only in
the form of inclusion bodies. The following temperature
adjustment during induction didn’t change the situation
and just affected the amounts of expression. Finally, the
induction was performed under 42 °C for 5 h since
the expressing amount did not increase over a longer
period of time and then rmRetn was purified from in-
clusion bodies.
To prepare enough inclusion bodies, 500 ml LB medium
culture of E. coli BL21 (DE3) harboring pET28a-mRetn
were induced under the optimized condition, totaling
200 mg (wet weight) inclusion bodies obtained.
Denaturing and refolding results
100 mg inclusion bodies were thoroughly solubilized in
10 ml denaturing buffer, and only a little pellet of pre-
cipitation was found after centrifugation. The protein in
clear supernatant was refolded by gradual dilution into a
renaturing buffer at 0.2 ml/min, nearly half (45 %) of the
inclusion bodies were refolded successfully and they
turned out to be soluble after centrifugation (Fig. 2c).
Ion-exchange chromatography result
Diluted in the same volume of balance buffer, rmRetn was
loaded onto an anion-exchange (Q sepharose) column
and then a cation-exchange (SP Sepharose) column. The
protein was eluted out directly by a binding buffer and
was bound on SP Sepharose resin. A single peak of
rmRetn was eluted out by increasing the gradient salt
when conductivity reached 30 mS/cm, corresponding to
0.684 M NaCl, after the signal of impurities reached zero
(Fig. 2d). The fractions collected under monitoring were
analyzed on SDS-PAGE and then combined, and finally
1.8 mg rmRetn was obtained in 4.2 ml elution buffer
(Fig. 2e).
Characterization and quality analysis of purified rmRetn
The final product could be decided undoubtedly to be
rmRetn because the cDNA had been sequenced cor-
rectly and the actual molecular weight on SDS-PAGE
was unanimous with calculations. Furthermore, the pro-
tein could also bind to an anti-mRetn antibody in the
western blotting assay (Fig. 2f ).
The quality was evaluated mainly through purity and
endotoxin analysis. On the SDS-PAGE gel, there was only
one band that could be seen, which indicated that the re-
combinant protein was already very pure. The purity was
further analyzed by RP-HPLC and SEC-HPLC, and a dif-
ferent material, occuping 2.4 % of total peak area, was de-
tected on RP-HPLC spectrum. Thus, the purity of rmRetn
was determined to be 97.6 % (Fig. 3a). The SEC-HPLC
analysis identified only one peak of rmRetn and no multi-
mers of it, for example the trimers and hexamers that had
been reported in the past articles [18, 19] (Fig. 3b). As a
result, 4.7 mg in 13 ml and 6.7 mg in 7 ml of purified
rmRetn were recovered after the combination of fraction
1 and 3. Endotoxin of the purified rmRetn, previously de-
termined as prescribed, was less than 1 EU/μg, which was
considered to be acceptable for animal use [20].
Fig. 1 Upregulation of Retn in BM cells after ablation. a Normal Balb/c mice were injected with 5-Fu (300 mg/kg) or PBS as control at day 0. Total
BM cell numbers per leg decreased remarkably post 5-Fu injection compared to the control (P < 0.001). 6 mice (3 males and 3 females) were
individually investigated at each time point in 3 independent experiments. b Gene expression analysis in the Affymetrix oligonucleotide microarrays.
Total mRNA of BM cells of mice was extracted at day 0, 3, 7, 11 and 14 post 5-fluorouracil injection and mixed thoroughly for genechip hybridization. 6
mice were utilized at every time point after chemotherapy, respectively. Microarray hybridizations were performed on gene chip Affymetrix mouse
genome 430 2.0. The hybridization intensities of Retn were shown at 0, 3, 7, 11, 14 days after 5-Fu treatment. The mRNA level of mResistin reached the
maximum of 16.3 fold of the normal level on the 7th day after chemotherapy. c Serum samples obtained from PB were assayed for Retn by ELISA.
Samples of 3 mice at each time point were analyzed individually, and great increase was detected by day 7 (*P = 0.008) and 11 (*P = 0.003) after
chemotherapy, compared with the basic concentration at day 0. All values were given as mean ± SD
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Bioactivity analysis result of rmRetn
Both human and mouse Retn have been reported to be
able to promote endothelial cell activation [21, 22], pro-
liferation and migration [16, 23]. Here, a transwell ex-
periment was designed to investigate the migration
promoting bioactivity of rmRetn on MAECs, and the
concentrations of rmRetn used were referred to the pre-
vious report [16]. The cell migration results were shown
in Fig. 4a. Compared to the control, rmRetn at both 100
and 1000 ng/ml attracted more cells to transfer into the
bottom chamber. The groups showed significant differ-
ences between each other after 8 h. As a whole, rmRetn
promoted MAECs to migrate in both time- and dose-
dependent manners and the effects were exact and
specific. The results indicated obviously that the prepared
rmRetn possessed the bioactivity of mRetn and was suit-
able for animal experiments.
rmResisitin increased bone marrow CFU of mice in vitro
When cultured in medium with rmRetn, mouse bone
marrow cells responded significantly to the protein at
concentrations of 0.1 μg/ml (p < 0.001, n = 3) and 1 μg/
ml (p < 0.01, n = 3), compared to the control group with
PBS (Fig. 4b). Moreover, the effect was dose-dependent.
The results indicated undoubtedly that rmRetn could ac-
tivate the bone marrow cells and promote their prolifer-
ation, which means that the bone marrow cells were
motivated and entered into active cell cycles from the
Fig. 2 Cloning, expression, purification and characterization of rmResistin. a: Construction of rmRetn expression plasmid, and arrow indicates the
PCR product, of mResistin ORF, which contains 288 base pairs and codes 94 amino acids of mature mResistin with an additional initiating codon
on 5’ terminus and a stop codon on 3’ terminus. M, marker; 1, PCR product of rmResistin expression plasmid verification. b: Compared with
whole bacteria proteins without induction, a protein band, as arrow indicates, appears after induction with IPTG. M, marker; 1, whole bacterial
proteins prior to induction; 2, whole bacterial proteins 4 h post induction with 1 mM IPTG. c: Inclusion bodies of rmResistin were dissolved in
denaturing buffer of GdnHCl (lane 1) and renatured in renaturing buffer (lane 3). The impurities and unsuccessfully renatured inclusion bodies
(lane 2) were removed. M, marker; 1, solubilized inclusion bodies; 2, pellet of centrifugation post renaturation; 3, the renatured protein solution.
d: Loaded on the SP sepharose Fast Flow resins, rmResistin was washed and eluted with linear NaCl concentration from 0.02-1 M and the only
UV280 peak, eluted out when conductivity reached, as the arrow indicates, shows rmResistin. Absorbance at 280 nm and conductivity were
detected on monitor. The elution was fractioned into fraction 1, 2 and 3. e: Three fractions were subjected to 15 % SDS-PAGE and only one band
with molecular weight about 10.4 KDa was observed in the three lanes; M, molecular weight marker; 1, fraction 1; 2, fraction 2; 3, fraction 3.
f: Western blotting results of rmResistin. Only one band positioned at about 10.4 KDa was obverved and this was identified as rmRsisitin monomer. No
dimmers, trimers or polymers of rmResistin were found. M, Molecular weight standard marker; 1, whole bacterial proteins containing induced rmresistin
by IPTG; 2, purified rmResistin
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quiescent state. Thus, if subjected to rmRetn at a suit-
able concentration, mouse BM cells might increase to a
higher level than normal, and the deduction was proved
to be true in the following experiment.
rmRetn increased hematocytes of normal mice in vivo
As expected, the number of total bone marrow cells was
significantly increased on the fifth day after the rmRetn
injections at doses of 50 and 500 ug/kg/day (p < 0.05,
n = 16; p < 0.01, n = 16; Fig. 4c). Although the cell
number at the lowest dose (5 μg/kg/day) did not differ
meaningfully from the control group, the increasing
averages of cell number demonstrated that the hemo-
stimulating effect was probably in a dose-dependent
manner. Additionally, the percentage of S phase of bone
marrow cells was raised distinctly after the rmRetn
injections (p < 0.05, n = 16; p < 0.01, n = 16; Fig. 4d). On
day 10 post rmRetn injection, the BM cell number and
percentage of S phase did not show any change and this
was might due to the elimination of rmRetn in the
blood circulation and the BM cells went back to being
quiescent again.
rmRetn increased mouse survival from acute lethal
toxicity of 5-Fluorouracil
Since the hematopoiesis of BM was motivated by rmRetn,
it could probably protect mice from the hematoxity in-
duced by chemotherapy agents, just as G-CSF could pro-
tect mice neutrophils from chemotherapy. When treated
at the lethal dose (300 mg/kg) as previously used in our
labarotory [20], all mice died on day 11, namely 5 days
post chemotherapy. However, admisnistration of rmRetn
following the 5-flurouracil injection, reduced the mortality
rate of mice, and prolonged the survival period of the ani-
mals. The survival rates of these two groups differed sig-
nificantly (p < 0.05, n = 15; Fig. 4e). Meanwhile, a group of
mice were especially useful here to verify the hemo-
stimulating effect from the other side. Pretreatment of
rmRetn might motivate BM cells before chemotherapy,
and these active cells would be more sensitive and feasible
to chemotherapic agents, exacerbating the toxicity and in-
ducing more lethality. And the results confirmed the hy-
pothesis as shown in Fig. 4e. Although the difference of
the survival rate between the pretreatment group and the
control chemotherapy group was not significant (p > 0.05,
n = 15), the survival period of animals in the chemother-
apy group was obviously prolonged. When the rmRetn
pretreatment group was compared with the rmRetn post-
treatment group, the survival rate was extremely different
(p < 0.001, n = 15). These results indicated that rmRetn
might be a protective agent against the acute lethal tox-
icity of chemotherapy for mice.
Discussion
In this study, we attempted to verify the hypothesis de-
rived from the genechip hybridization and to determine
whether mouse Retn could exert effects on hematopiesis
in mice. Firstly, a cost-effective and feasible producing
process was designed to prepare enough protein for the
animal experiments. Expression, purification, denatur-
ation, and renaturation of rmRetn were all utilized in the
process successively to prepare the soluble protein. Ion
exchange chromatographies were applied to remove im-
purities. The advantages of recovering a biologically
active protein from inclusion bodies, such as highly
enriched targeted protein, is the resistance to proteolysis
by E. coli proteases and the convenience to isolate from
host strain. More importantly, it facilitates highly pure
protein production [24, 25]. Thus, a successful strategy
was employed here to recover enough pure rmRetn with
low level of endotoxin for use.
As to animal studies, 5-FU model is one of the most
common model for researching BM suppression and re-
generation post chemotherapy. In our work, it suits well.
The possible role of Retn in hematopoiesis is suggested
by our results: (1) the temporal induction of Retn ex-
pression in BM cells inversely suits the BM cellularity
Fig. 3 HPLC analysis results of purified rmRetn. a: RP-HPLC analysis
of purified rmRetn was employed to detect sulphoxides, deamidates
and/or impurities. Totally 28.5 μg rmRetn in 30 μl was loaded for
analysis and two peaks were observed in the RP-HPLC spectrum, with
the large one (1) identified as rmRetn and minor one (2) as other
material. The purity by RP-HPLC was 97.6 %; b: SEC-HPLC was
performed to detect possible polymers of rmRetn. Totally 47.5 μg
rmRetn in 50 μl was loaded for analysis and only one rmRetn peak (1)
was checked in SEC-HPLC spectrum and the purity of rmRetn was
100 %. Both spectra were detected at ultra violet (UV) wave
length 280 nm and had been divided by blank control
spectra respectively
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Fig. 4 Results of bioactivity determination and hemotopoiesis investigation of rmRetn on mouse BM. a: Migration of MAECs was accelerated by
rmRetn at 100 or 1000 ng/ml after incubation of 8 h compared with control (p = 0.0049 and p < 0.001, n = 3); After incubation of 4 h, 100 ng/ml
group didn’t exhibit significant difference from control group (p > 0.05, n = 3), while migrated number of 1000 ng/ml group was extremely
significant compared with control group (p = 0.0034, n = 3). b: CFU numbers of BM per plate in the presence of rmRetn (100 and 1 000 ng/ml)
were significantly increased compared with control (p < 0.001 and p = 0.0087, n = 3). c: Total BM cell numbers of normal mice were increased
significantly after continuous administeration of rmRetn for 5 days, twice per day, at the dose of 50 and 500 μg/kg compared with control (PBS)
group (p < 0.001 and p = 0.0036 respectively, n = 16) except for 5 ng/kg group (p > 0.05, n = 16). While the difference didn’t exist at day 10 after
continuous administration of rmRetn at all the three doses of 7 days (p > 0.05, n = 16). d: Percentage of S phase of BM cells was raised largely
after continuous administeration of rmRetn for 5 days, twice per day, at the dose of 50 and 500 μg/kg compared with control (PBS) group
(p < 0.001 and p = 0.0036 respectively, n = 16) except for 5 ng/kg group (p > 0.05, n = 16). While the difference didn’t exist at day 10 after
continuous administration of rmRetn at all the three doses of 7 days (p > 0.05, n = 16). e: Pretreatment and postreatment of rmRetn displayed
thoroughly reverse effects on mice injected with 5-fluorouracil (300 mg/kg). Adminsteration of rmRetn post 5-fluorouracil treatment prolonged
the life time of animals and saved two mice from the chemotoxicity of 5-Fluorouracil compared to the zone survival in control group (with only
5-fluorouracin injected) (p = 0.024, n = 15); However, the animals with mRetn pretreatment had a shorter life span than the control animals.
Although the difference between pretreatment group and control group wasn’t statistically meaningful (p > 0.05, n = 15), the difference between
pre- and post-treatment group was statistically meaningful (p < 0.001, n = 15); The result indicated that post-treatment of rmRetn could protect
mice from the toxicity of 5-fluorouracil and increased their survival rate
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after 5-Fu induced suppression and regeneration. This sug-
gests a role of Retn involving BM homeostasis; (2) elevation
of Retn by administration of recombinant protein sig-
nificantly increases the numbers of HPCs (hematopoietic
progenitor cells) tested by cell proliferation-stimulating
activity (CFU) test in vitro, and circulating Retn by
injection of recombinant protein significantly raises the
numbers of BM cells in vivo through promoting the
progression of BM cell cycle; and (3) as a consequence of
its promotion of cell cycle entry into S phase, elevation of
Retn plasma levels after 5-Fu treatment magnificently
alleviates mouse mortality.
In summary, the hypothetical hematopoiesis of mRetn
was confirmed by BM CFU assay, BM cell proliferation
assay and survival assay in vitro and in vivo [26]. All the
results of these assays demonstrated that rmRetn might
help accelerate BM recovery from 5-fluorouracil through
activating BM cells, which suggested that Retn might
play a protective role during chemotherpy in clinic.
Compared to a supressive agent of BM hematopoiesis
used prior to chemotherapy [20] such as G-CSF [27],
mRetn takes a direct effect on BM cells post chemother-
apy, which might take a more significant effect com-
pared to the former. As one of the most serious side
effects of cancer chemotherapy and radiotherapy, hema-
topoietic system impairs often leads to neutropenia which
is currently treated with G-CSF [28] as the first resort.
Therefore, the hematopoiesis of mRetn will be our next
emphasis. Of couse, the mechanism of motiviating BM
cells is still mysterious and will be focused on in the
following work.
The direct evidence was rarely observed about hema-
topoiesis of Retn, while indrect evidences, including our
genechip data, have been reported repeatedly. Retn plays
roles mainly in inflammation, glucose metabolism and
insulin resistance [29, 30]. Recently, Retn was proved to
be able to induce human endothelial cell proliferation,
migration and in vitro angiogenesis through activating
ERK1/2 and p38 [23]. These findings provide a direct
link between Retn and angiogenesis. Furthermore, both
Retnlg, an important member of the Retn family, and
human RETN are expressed in myeloid cells with the
highest levels found in the bone marrow [11, 31]. The
previous information delivers a message that Retn joins
not only in the vascular lesion formation, but also in
haematopoietic cell development. Until the mechanisms
of the stimulating effects on the BM cells of rmRetn are
identified, the utilization of Retn for the regulation of
whole blood circulation system, and for cancer chemo-
therapy and radiotherapy can not be understood.
Conclusions
In summary, we prepared a sufficient amount of rmRetn
with high-purity, high biological activities and low
endotoxin level by a feasible and economic way, which
totally matches the native mouse Resistin in sequence
with no additional tag, and presented new effects of
rmResistin then verified our hypothesis that mRetn can
activate BM cells to resist the toxicity of chemopeutical
agents, which was derived from our genechip data. It
was the first time that the possible hematopoiesis effect
of mRetn was identified and proven, which may reduce
the side effects induced by chemotherapy and help can-
cer patients survive from chemotherapy and improve
their quality of life. As to why rmRetn can help acceler-
ate the HSC division of mice still needs to be investi-
gated, which we will carry out in the further.
Most importantly, we hope that, with our method, the
ability to produce milligram quantities of bioactive protein
from E. Coli and the investigation of protein function will
facilitate the study of biochemical and pathological roles
of Resistin.
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